Show simple item record

dc.contributor.authorNdefo, U A
dc.contributor.authorOkoli, O
dc.contributor.authorErowele, G
dc.date.accessioned2014-07-05T16:46:21Z
dc.date.available2014-07-05T16:46:21Z
dc.date.issued2014-01-15
dc.identifier.citationAlogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. 2014, 71 (2):103-9 Am J Health Syst Pharmen_GB
dc.identifier.issn1535-2900
dc.identifier.pmid24375601
dc.identifier.doi10.2146/ajhp130131
dc.identifier.urihttp://hdl.handle.net/10144/322484
dc.description.abstractThe pharmacology, pharmacodynamics, pharmacokinetics, safety, efficacy, and place in therapy of alogliptin and its combinations for managing type 2 diabetes mellitus are reviewed.
dc.language.isoenen
dc.publisherAmerican Society of Health System Pharmacistsen_GB
dc.rightsArchived with thanks to American Journal of Health-System Pharmacy (AJHP): Official Journal of the American Society of Health-System Pharmacistsen_GB
dc.subjectNon-communicable diseasesen_GB
dc.subjectOtheren_GB
dc.titleAlogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitusen
dc.identifier.journalAmerican Journal of Health-System Pharmacyen_GB
refterms.dateFOA2019-03-04T11:20:06Z
html.description.abstractThe pharmacology, pharmacodynamics, pharmacokinetics, safety, efficacy, and place in therapy of alogliptin and its combinations for managing type 2 diabetes mellitus are reviewed.


Files in this item

Thumbnail
Name:
Ndefo et al-2014-Alogliptin-A ...
Size:
3.070Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record